title: The role of sevista in the management of dysfunctional uterine bleeding.
abstract: OBJECTIVE
  The complaints of excessive menstrual bleeding (menorrhagia) have a substantial impact on the gynaecological services and in most of the cases, no organic pathology is identified. Nonsteroidal anti-inflammatory drugs and tranexamic acid offer a simple therapy which has to be taken during menses, with reductions of 25-35% and 50% respectively in the Menstrual Blood Loss (MBL). Danazol and the gonadatrophin-releasing hormone analogues are highly effective, but their side-effects make them suitable only for a short-term use. In the present study, the role of ormeloxifene was studied in patients of DUB.
  
  
  METHODS
  The subjects were diagnosed cases of DUB. After ruling out the possible causes of the abnormal uterine bleeding, a diagnosis of DUB was made and the treatment with ormiloxifene was started. The number of cases were 35 cases. The treatment with ormeloxifene was evaluated by measuring the Hb g/dl and the endometrial thickness before and after 3 months of treatment with sevista. Ormeloxifene was given in the dosage of a 60 mg tablet twice a week for 3 months, followed by once a week for another 3 months.
  
  
  RESULTS
  There was a statistically significant increase in the Hb g/dl (p < 0.001) and a statistically significant decrease in the endometrial thickness (p< 0.001) after the treatment with ormeloxifene.
  
  
  CONCLUSIONS
  Ormeloxifene can be used asa effective drug in the treatment of Dysfunctional uterine bleeding.
authors: Professor, Department of OBG, Sri Siddhartha Medical College Tumkur - 572107 Affiliated to Sri Siddhartha University.
authors: Dhananjay
authors: D
authors: Bs
authors: Sunil Kumar
authors: SK
authors: Nanda
keywords: Dysfunctional uterine bleeding; Endometrial thickness; Ormeloxifene